CYTRX CORP
10-Q, EX-27.2, 2000-08-10
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CYTRX CORP, 10-Q, EX-27.1, 2000-08-10
Next: RENTRAK CORP, 10-Q, 2000-08-10



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<RESTATED>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999             DEC-31-1999
<PERIOD-START>                             APR-01-1999             JAN-01-1999
<PERIOD-END>                               JUN-30-1999             JUN-30-1999
<CASH>                                      10,032,870              10,032,870
<SECURITIES>                                         0                       0
<RECEIVABLES>                                  151,975                 151,975
<ALLOWANCES>                                         0                       0
<INVENTORY>                                      5,747                   5,747
<CURRENT-ASSETS>                            10,278,136              10,278,136
<PP&E>                                       1,246,649               1,246,649
<DEPRECIATION>                               (516,742)                (516,742)
<TOTAL-ASSETS>                              11,079,021              11,079,021
<CURRENT-LIABILITIES>                        1,539,232               1,539,232
<BONDS>                                              0                       0
                                0                       0
                                          0                       0
<COMMON>                                         8,267                   8,267
<OTHER-SE>                                   9,531,522               9,531,522
<TOTAL-LIABILITY-AND-EQUITY>                11,079,021              11,079,021
<SALES>                                         98,601                 164,331
<TOTAL-REVENUES>                               499,282                 818,351
<CGS>                                           37,570                 106,110
<TOTAL-COSTS>                                   37,570                 106,110
<OTHER-EXPENSES>                             3,047,966               6,566,203
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                   0                       0
<INCOME-PRETAX>                            (2,586,254)             (5,853,962)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                        (2,586,254)             (5,853,962)
<DISCONTINUED>                                (78,982)                (87,201)
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                               (2,665,236)             (5,941,163)
<EPS-BASIC>                                      (.35)                   (.78)
<EPS-DILUTED>                                    (.35)                   (.78)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission